Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 3 17Phase NA 10Phase 1 8Phase 1/2 7Phase 2/3 4Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 276Neoplasms 202Prostatic Neoplasms 118Polycystic Ovary Syndrome 114Colorectal Neoplasms 103Carcinoma, Hepatocellular 103Carcinoma, Non-Small-Cell Lung 88Lung Neoplasms 70Stomach Neoplasms 62Precursor Cell Lymphoblastic Leukemia-Lymphoma 60Pain 59Neoplasm Metastasis 54Multiple Myeloma 52Pancreatic Neoplasms 46Keratosis, Actinic 46Head and Neck Neoplasms 43Pain, Postoperative 42Leukemia, Myeloid, Acute 40Leiomyoma 39Recurrence 38Liver Neoplasms 38Colonic Neoplasms 37Uterine Cervical Neoplasms 35Lymphoma 35Brain Neoplasms 34Infertility 33Papillomavirus Infections 32Ovarian Neoplasms 31Lymphoma, Follicular 31Lymphoma, Non-Hodgkin 30

Interventions

pyrotinib 1Trastuzumab 1Taxoids 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × HER2-positive Breast Cancer × Clear all
NCT06217185 2024-02-28

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

Hebei Medical University Fourth Hospital

Phase 4 Recruiting
100 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡